Mometasone + Formoterol

Thông tin thuốc gốc
Chỉ định và Liều dùng
Adult: Available preparations:
Metered dose inhaler releasing mometasone 50 mcg and formoterol 5 mcg per actuation
Metered dose inhaler releasing mometasone 100 mcg and formoterol 5 mcg per actuation
Metered dose inhaler releasing mometasone 200 mcg and formoterol 5 mcg per actuation
2 puffs bid. Dose is titrated to the lowest effective dose and may be shifted to higher strength for adequate control of symptoms. Max 800 mcg/20 mcg.
Child: ≥12 yr Same as adult dose.
Chống chỉ định
As primary treatment of status asthmaticus, acute episodes of asthma, and during rapidly deteriorating or potentially worsening episode of asthma.
Thận trọng
Patient w/ severe asthma, risk factors for decreased BMD, CV disease (e.g. arrhythmia, coronary insufficiency, HTN, recent MI), DM, GI disease (e.g. diverticulitis, peptic ulcer, ulcerative colitis), myasthenia gravis, cataract/glaucoma, pheochromocytoma, seizure disorders, hypokalaemia, thyroid disease, bacterial (e.g. active or quiescent pulmonary TB), fungal, parasitic, and viral (e.g. chickenpox, measles, ocular herpes simplex) infections. Hepatic impairment. Childn. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Adrenal suppression, hypercorticism, immunosuppression, Kaposi sarcoma, oral candidiasis, psychiatric disturbances, decreased BMD, BP and heart rate elevation, CNS stimulation/excitation, risk of arrhythmias (e.g. AF, ventricular extrasystoles, tachyarrhythmia), ECG changes (e.g. flat T wave, prolonged QT interval, depressed ST segment), increased intra-ocular pressure, glaucoma, cataract, hypokalaemia, myasthenia gravis exacerbation, ketoacidosis aggravation, hyperglycaemia, risk of perforation. Rarely, vasculitis, hypersensitivity reactions (e.g. allergic dermatitis, angioedema, bronchospasm, arthralgia, flushing, rash, anaphylaxis, urticaria).
Nervous: Headache, tremor.
Resp: Nasopharyngitis, voice disorder, sinusitis.
Potentially Fatal: Asthma exacerbation, paradoxical bronchospasm.
Inhalation/Respiratory: C
Thông tin tư vấn bệnh nhân
Rinse mouth thoroughly every after inhalation. Avoid abrupt withdrawal.
Chỉ số theo dõi
Monitor FEV1, peak flow meter and/or other pulmonary function tests, BP, heart rate, serum glucose, serum K, BMD, and eye exam (chronic users). Monitor signs of asthma deterioration, growth in paediatric patients, symptom relief, HPA axis suppression, CNS stimulation.
Quá liều
Symptoms: Hypercorticism, angina, HTN or hypotension, tachycardia, arrhythmias, nervousness, headache, tremor, seizures, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, hypokalaemia, hyperglycaemia, insomnia, metabolic acidosis, cardiac arrest. Management: Symptomatic and supportive treatment.
Tương tác
Mometasone: Increased plasma concentration w/ strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, cobicistat-containing products).
Formoterol: Enhanced hypokalaemic effect w/ xanthine derivatives, or non-potassium sparing diuretics. May prolong QTc-interval and increase the risk of ventricular arrhythmias when used w/ quinidine, terfenadine, astemizole, macrolides, disopyramide, procainamide, phenothiazines, MAOIs, and TCA. Decreased therapeutic effect w/ β-adrenergic blockers. Increased risk of arrhythmias w/ halogenated hydrocarbons.
Tác dụng
Description: Mometasone is a synthetic nonfluorinated glucocorticoid. It prevents or reduce inflammation by controlling the rate of protein synthesis, depressing the migration of polymorphonuclear leukocytes/fibroblasts, and reversing capillary permeability and lysosomal stabilization at the cellular level.
Formoterol is a long-acting selective β2 adrenoceptor agonist. It relaxes bronchial smooth muscles by stimulation of adenyl cyclase, thereby increasing cyclic-3’- 5’-adenosine monophosphate (cAMP) levels.
Duration: Formoterol: Up to 12 hr.
Absorption: Mometasone: Rapidly absorbed. Absolute bioavailability: Approx 14%. Time to peak plasma concentration: 0.5-4 hr.
Formoterol: Rapidly absorbed. Time to peak plasma concentration: 0.17-1.97 hr.
Distribution: Mometasone: Volume of distribution: 152 L. Plasma protein binding: 98-99%.
Formoterol: Plasma protein binding: 61-64% (34% primarily to albumin).
Metabolism: Mometasone: Undergoes hepatic metabolism by CYP3A4 enzyme to 6-β hydroxymometasone furoate.
Formoterol: Metabolised via glucuronidation and O-demethylation.
Excretion: Mometasone: Mainly via faeces (74%); urine (8%, lesser extent). Terminal elimination half-life: Approx 5 hr.
Formoterol: Mainly via urine (approx 10% as unchanged drug). Terminal elimination half-life: Approx 10 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 441335, Mometasone. Accessed Oct. 26, 2022.

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Arformoterol, CID=3083544, (accessed on Jan. 21, 2020)

Bảo quản
Store between 20-25°C.
Phân loại MIMS
Thuốc trị hen & bệnh phổi tắc nghẽn mạn tính
Phân loại ATC
R03AK09 - formoterol and mometasone ; Belongs to the class of adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics. Used in the treatment of obstructive airway diseases.
Tài liệu tham khảo
Anon. Mometasone and Formoterol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 07/09/2017.

Buckingham R (ed). Formoterol Fumarate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 07/09/2017.

Buckingham R (ed). Mometasone Furoate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 07/09/2017.

Dulera Inhalation Aerosol (Merck Sharp & Dohme Corp.). DailyMed. Source: U.S. National Library of Medicine. Accessed 07/09/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Mometasone Furoate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 07/09/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Mometasone + Formoterol từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in